The Symbiotec Pharmalab IPO plans to channel Rs 112.50 crore towards the prepayment and/or repayment, fully or partially, of select outstanding borrowings, helping strengthen the company’s balance sheet and potentially reduce its debt burden.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.